Acos500 mg

Acos 500 mg is a broad-spectrum macrolide antibiotic and one of the most widely prescribed antibacterial agents worldwide. It is an erythromycin derivative with significantly enhanced activity against Gram-negative bacteria, including Enterobacteriaceae, while also providing reliable coverage against many Gram-positive organisms. Acos 500 mg is particularly effective against "atypical" bacteria such as Chlamydia trachomatis, Legionella pneumophila, Mycoplasma pneumoniae, and Mycobacterium avium — organisms that do not respond to standard beta-lactam antibiotics.

Respiratory Tract Infections

Acos 500 mg is indicated for community-acquired pneumonia (CAP) caused by susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. It is also used for acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD), acute bacterial sinusitis, acute otitis media (middle ear infection), and bronchitis.

Pharyngitis and Tonsillitis

Acos 500 mg is indicated for pharyngitis and tonsillitis caused by Streptococcus pyogenes, as a second-line alternative in patients who are allergic to or unable to take beta-lactam antibiotics such as penicillin.

Skin and Soft Tissue Infections

Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae can be effectively treated with Acos 500 mg.

Sexually Transmitted Infections (STIs)

Acos 500 mg is used to treat a range of sexually transmitted infections, including:

• Chlamydia — urethritis and cervicitis caused by Chlamydia trachomatis
• Gonorrhea — in combination with ceftriaxone or gentamicin for uncomplicated gonococcal infections (particularly in patients with cephalosporin allergy)
• Chancroid — caused by Haemophilus ducreyi
• Non-gonococcal urethritis and cervicitis — caused by Mycoplasma genitalium

Mycobacterium avium Complex (MAC)

Acos 500 mg is indicated for the treatment and long-term prophylaxis of Mycobacterium avium complex (MAC) infections in patients with advanced HIV/AIDS.

Gastrointestinal Infections

Acos 500 mg is used off-label for enteric fever (typhoid) caused by Salmonella typhi, particularly in cases resistant to other antibiotics. It is also effective for Campylobacter gastroenteritis and traveler's diarrhea.

Additional and Off-Label Uses

• Cystic Fibrosis: Long-term Acos 500 mg therapy is recommended by the Cystic Fibrosis Foundation for patients 6 years and older with persistent Pseudomonas aeruginosa infection, to improve lung function and reduce exacerbations.
• Babesiosis: In combination with atovaquone — the preferred regimen per the IDSA.
• Bronchiolitis obliterans prophylaxis: After lung transplantation.
• Pelvic Inflammatory Disease (PID): As part of combination regimens.
• Malaria: Off-label use in combination with antiprotozoal agents such as atovaquone.

Note: Acos 500 mg has no proven efficacy against viral infections, including COVID-19, RSV, or influenza. It should only be used for confirmed or clinically suspected bacterial infections.

Macrolide Antibiotics (Azalide subgroup)

Acos 500 mg is a semi-synthetic macrolide (azalide) antibiotic derived from erythromycin. It has a broad spectrum of antibacterial activity and unique pharmacokinetic properties that distinguish it from older macrolides.

Mechanism of Action

Acos 500 mg works by binding to the 23S ribosomal RNA of the 50S bacterial ribosomal subunit. This binding inhibits bacterial protein synthesis by blocking the translocation of aminoacyl-tRNA and the elongating peptide chain through the ribosome — effectively halting the production of proteins essential for bacterial survival and reproduction.

Acos 500 mg is primarily bacteriostatic (inhibits bacterial growth), but at higher concentrations it exerts a bactericidal effect against certain organisms such as Streptococcus spp. and Haemophilus influenzae. It is less prone to dissociation from Gram-negative ribosomes compared to erythromycin, which accounts for its superior activity against Gram-negative pathogens.

In addition to its antibacterial properties, Acos 500 mg has significant immunomodulatory effects — it reduces airway neutrophilia, suppresses IL-8 gene expression, and lowers C-reactive protein (CRP) levels, making it beneficial in inflammatory airway conditions such as cystic fibrosis and COPD.

Spectrum of Activity

• Gram-positive bacteria: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae
• Gram-negative bacteria: Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, Escherichia coli, Salmonella spp., Campylobacter spp.
• Atypical organisms: Chlamydia trachomatis, Mycoplasma pneumoniae, Legionella pneumophila, Ureaplasma urealyticum
• Mycobacteria: Mycobacterium avium complex

Pharmacokinetics

• Absorption: The oral bioavailability of a 250 mg dose is approximately 38%. When the oral suspension is taken with food, peak plasma concentration (C_max) increases by 56%, although the total AUC remains unchanged. Capsule forms should be taken on an empty stomach.
• Distribution: Acos 500 mg is extensively distributed into tissues and has excellent intracellular penetration. It achieves high concentrations in the skin, lungs, tonsils, prostate, uterus, cervix, liver, and gallbladder. It is highly concentrated in phagocytes, with an intracellular-to-extracellular ratio exceeding 30:1 — allowing delivery of the drug directly to sites of infection.
• Protein Binding: Variable — ranging from 51% at low concentrations to 7% at higher concentrations.
• Metabolism: Primarily hepatic. Acos 500 mg is metabolized in the liver and excreted largely via bile.
• Half-life: Approximately 68 hours — one of the longest half-lives among oral antibiotics. This enables once-daily dosing and short treatment courses (typically 3–5 days) that provide equivalent clinical outcomes to longer regimens with other antibiotics.
• Elimination: Primarily via biliary excretion into the feces; approximately 6% is excreted unchanged in the urine.

Oral Tablets and Capsules

• Acos 500 mg tablets may be taken with or without food.
• Capsules should be taken at least 1 hour before or 2 hours after meals, as food significantly reduces absorption from capsule formulations.
• Swallow tablets or capsules whole with a full glass of water. Do not crush or chew.
• Do not take aluminum- or magnesium-containing antacids simultaneously with Acos 500 mg, as they may reduce peak serum concentration by up to 24%. If antacids are needed, take them at least 2 hours apart.
• Complete the full prescribed course even if symptoms improve early — stopping treatment early may allow bacteria to survive and cause a relapse.

Oral Suspension

• Acos 500 mg oral suspension can be taken with or without food.
• Shake the suspension well before each use.
• Use the measuring spoon or oral syringe provided to ensure accurate dosing. Do not use a regular household teaspoon.
• Store constituted suspension between 5°C and 30°C and discard any unused portion after the course is complete.

IV Infusion (Intravenous)

• Acos 500 mg IV infusion is reserved for patients who require hospitalization or cannot take oral medications.
• Administer by slow IV infusion over 60 minutes for a 500 mg dose diluted in at least 250 mL of compatible IV fluid (e.g., Normal Saline 0.9% or 5% Dextrose in Water).
• Do not administer as a rapid IV bolus injection — this can cause severe hypotension.
• Visually inspect the reconstituted solution for particulate matter and discoloration before use. Discard if present.
• Once diluted, the infusion solution is stable for 24 hours at room temperature (≤30°C) or up to 7 days when refrigerated (5°C).
• Switch to oral Acos 500 mg as soon as the patient can tolerate oral medications (step-down therapy).

Acos 500 mg has a number of clinically important drug interactions that require careful monitoring or avoidance:

QT-Prolonging Drugs (Avoid Combination)

Acos 500 mg prolongs the cardiac QTc interval. Combining it with other QT-prolonging drugs significantly increases the risk of life-threatening arrhythmias, including torsades de pointes. Drugs requiring avoidance or extreme caution include:

• Antiarrhythmics: amiodarone, sotalol, quinidine
• Antipsychotics: haloperidol, quetiapine, ziprasidone
• Fluoroquinolones: moxifloxacin, levofloxacin
• Antimalarials: chloroquine, hydroxychloroquine
• Buprenorphine (long-acting injection or implant)
• Crizotinib and other oncology agents with QT effects

Antacids (Aluminum and Magnesium)

Aluminum- and magnesium-containing antacids may reduce peak plasma concentrations (C_max) of Acos 500 mg by up to 24%. Patients should take Acos 500 mg and antacids at least 2 hours apart.

Colchicine (Contraindicated)

Acos 500 mg inhibits the P-glycoprotein (P-gp) efflux transporter, which can significantly increase colchicine plasma levels, raising the risk of colchicine toxicity — including GI disturbances, fever, myalgia, pancytopenia, and multi-organ failure. Concurrent use is contraindicated in patients with renal or hepatic impairment and should be avoided or used with extreme caution in others.

Warfarin and Anticoagulants

Acos 500 mg may potentiate the anticoagulant effect of warfarin by altering gut flora and disrupting vitamin K absorption. INR should be closely monitored during and after Acos 500 mg therapy.

Digoxin

Acos 500 mg may increase digoxin plasma levels by altering gut flora, potentially leading to digoxin toxicity. Digoxin levels should be monitored during co-administration.

Pimozide (Contraindicated)

Concurrent use of Acos 500 mg with pimozide (an antipsychotic) is contraindicated. Acos 500 mg can increase pimozide plasma levels through CYP3A4 inhibition, leading to dangerous cardiac arrhythmias.

CYP3A4-Metabolized Drugs

Acos 500 mg can inhibit the CYP3A4 enzyme, potentially increasing blood levels of drugs metabolized through this pathway. Drugs such as cobicistat, cyclosporine, and certain statins may be affected. Consult current drug interaction databases when prescribing concurrently.

Live Bacterial Vaccines

Acos 500 mg may reduce the effectiveness of live bacterial vaccines (e.g., BCG vaccine, cholera vaccine). Live vaccines should not be administered until at least 14 days after completing Acos 500 mg therapy.

Acos 500 mg is generally well tolerated. Most adverse effects are mild to moderate and resolve upon completion or discontinuation of therapy. Fewer than 1% of patients stop treatment due to side effects.

Very Common (More than 10%)

• Abdominal pain or cramping
• Diarrhea or loose stools (most frequent at approximately 5%)
• Nausea (approximately 3%)
• Flatulence

Common (1–10%)

• Vomiting
• Dyspepsia (indigestion)
• Fatigue and general weakness
• Decreased appetite
• Taste disturbances (dysgeusia)
• Headache and dizziness

Uncommon to Rare

• Cardiac: QTc interval prolongation, which in rare cases can lead to life-threatening arrhythmias including torsades de pointes. Risk is higher in patients with pre-existing heart conditions or electrolyte abnormalities.
• Hearing: Reversible hearing loss, tinnitus, and hearing disturbances — particularly with high doses or prolonged use.
• Hepatic: Elevated liver enzymes, cholestatic jaundice, and in rare cases life-threatening hepatotoxicity. Discontinue immediately if signs of liver injury appear (dark urine, jaundice, pale stools, right upper quadrant pain).
• Hypersensitivity Reactions: Skin rash, urticaria, angioedema, and anaphylaxis. Serious cutaneous reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), DRESS syndrome, and Acute Generalized Exanthematous Pustulosis (AGEP) have been reported — discontinue immediately if these are suspected.
• Neurological: Confusion, agitation, and in very rare cases hallucinations.
• Musculoskeletal: Rare cases of exacerbation of myasthenia gravis have been reported.
• Superinfection: Clostridioides difficile-associated diarrhea (CDAD) and oral/vaginal candidiasis may occur with prolonged use due to disruption of normal flora.

Important: Discontinue Acos 500 mg immediately and seek medical attention if signs of a severe allergic reaction, cardiac symptoms (palpitations, dizziness, fainting), or signs of hepatic toxicity develop.

Pregnancy

Available human data on the use of Acos 500 mg during pregnancy have not identified any drug-related risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies in rats and mice using oral doses during organogenesis did not reveal evidence of teratogenicity or fetal malformations. However, Acos 500 mg should be used during pregnancy only when clearly necessary and when the potential benefit to the mother outweighs any potential risk to the fetus. Medical supervision is essential. The IV formulation is recommended only during pregnancy when no suitable alternative exists.

Lactation

Acos 500 mg is excreted into human breast milk in small amounts. Limited published data suggest that short-term use results in estimated infant daily doses of approximately 0.1 to 0.7 mg/kg/day — generally considered low and unlikely to cause harm to a healthy, full-term infant. However, infants should be monitored for potential gastrointestinal effects (diarrhea, candidiasis, thrush, or diaper rash). There is some unconfirmed epidemiological evidence suggesting that maternal macrolide use in the first 2 weeks of breastfeeding may be associated with infantile hypertrophic pyloric stenosis; however, two meta-analyses have not confirmed this relationship. Consult a physician before using Acos 500 mg while breastfeeding.

Fertility

There is no evidence that Acos 500 mg adversely affects human fertility.

Cardiac QT Prolongation

Acos 500 mg has been shown to prolong the cardiac QTc interval, which can cause potentially fatal arrhythmias such as torsades de pointes. Use with caution — or avoid entirely — in patients with known QT prolongation, hypokalemia, hypomagnesemia, bradycardia, or those taking other QT-prolonging drugs. ECG monitoring may be warranted in high-risk patients.

Severe Hypersensitivity Reactions

Serious allergic reactions — including anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), DRESS syndrome, and AGEP — have been reported, some with fatal outcomes. If any allergic reaction occurs, Acos 500 mg must be discontinued immediately and appropriate emergency therapy initiated.

Hepatotoxicity

Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure (occasionally fatal) have been reported during Acos 500 mg therapy. Monitor for signs of liver damage (nausea, fatigue, dark urine, jaundice) and discontinue treatment if hepatic dysfunction develops. Acos 500 mg is contraindicated in patients with pre-existing severe hepatic disease.

Superinfection and C. difficile-Associated Diarrhea

As with all broad-spectrum antibiotics, prolonged Acos 500 mg use may result in overgrowth of non-susceptible organisms, including Clostridioides difficile. Patients who develop severe, persistent, or bloody diarrhea during or after treatment should be evaluated for CDAD immediately.

Myasthenia Gravis

Acos 500 mg has been reported to exacerbate symptoms of myasthenia gravis. Use with caution in patients with this neuromuscular condition.

Infants Under 6 Weeks

Acos 500 mg should be used with caution in neonates and infants under 6 weeks of age due to a potential risk of hypertrophic pyloric stenosis (HPS). Monitor for signs of HPS, including projectile vomiting and feeding intolerance.

Antacids

Patients should not take aluminum- or magnesium-containing antacids at the same time as Acos 500 mg, as these can reduce its peak plasma concentration. Separate administration by at least 2 hours.

Antimicrobial Resistance

Long-term use of Acos 500 mg — particularly for COPD or cystic fibrosis prophylaxis — may increase macrolide resistance among colonizing bacteria. Patients should be screened for nontuberculous mycobacteria before initiating long-term therapy.

Driving and Machinery

Acos 500 mg may cause dizziness or confusion in some patients. Patients should assess their individual response before driving or operating heavy machinery.

There is no specific antidote for Acos 500 mg overdose. Overdosage may produce the following:

• Severe nausea, vomiting, and abdominal pain
• Diarrhea
• Temporary hearing loss or tinnitus
• Significant QTc interval prolongation with risk of serious cardiac arrhythmias
• Possible hepatic toxicity at very high doses

Management is symptomatic and supportive. Cardiac monitoring (ECG) is recommended in suspected overdose cases due to the risk of QT prolongation. In the event of a suspected overdose, contact a poison control center or seek emergency medical care immediately. Acos 500 mg is not efficiently removed by hemodialysis due to its extensive tissue distribution and protein binding.

• Store tablets and dry powder below 30°C (86°F), in a cool, dry place protected from direct light and moisture.
• Oral suspension (after constitution): Store between 5°C and 30°C (41°F–86°F). Discard any remaining suspension after the course of treatment is complete.
• IV vials (before reconstitution): Store at or below 30°C (86°F). Once diluted for infusion, the solution is stable for 24 hours at room temperature or up to 7 days when refrigerated at 5°C.
• Keep all formulations out of the reach of children.
• Do not use any formulation beyond the expiry date printed on the label or packaging.
• Do not freeze the reconstituted oral suspension or the IV infusion solution.

Pediatric Patients

Acos 500 mg oral suspension is approved for use in children aged 6 months and older for community-acquired pneumonia, acute otitis media, and acute bacterial sinusitis. For pharyngitis and tonsillitis, it is approved for children aged 2 years and older. The oral suspension single-dose packet (1 g) and IV formulations have not been established as safe and effective in patients under 18 years of age. Doses are weight-based; precise calculation by the prescribing physician is essential.

Elderly Patients

No dosage adjustment is required based on age alone. However, elderly patients are at higher risk of cardiac arrhythmias (especially QTc prolongation and torsades de pointes), and appropriate caution should be exercised. Pre-treatment ECG assessment may be warranted in high-risk elderly patients.

Patients with Renal Impairment

No dose adjustment is required for patients with mild to moderate renal impairment (GFR >10 mL/min). However, Acos 500 mg should be used with caution in patients with severe renal impairment, as the pharmacokinetics have not been fully studied in this population.

Patients with Hepatic Impairment

Since Acos 500 mg is metabolized and excreted primarily by the liver, it is contraindicated in patients with severe hepatic disease. In those with mild to moderate liver impairment, Acos 500 mg should be used with caution and liver function monitored during therapy.